Syphilis Testing Market Forecasts to 2032 – Global Analysis By Type (Primary Syphilis, Secondary Syphilis, Congenital Syphilis, Latent Syphilis, and Other Types), Location of Testing, Technology, Distribution Channel, Application, End User, and By Geograp
Description
According to Stratistics MRC, the Global Syphilis Testing Market is accounted for $2.49 billion in 2025 and is expected to reach $4.49 billion by 2032 growing at a CAGR of 8.8% during the forecast period. Syphilis testing refers to clinical procedures aimed at identifying infection caused by Treponema pallidum, the bacterium that leads to syphilis. Diagnostic methods typically include blood-based non-treponemal and treponemal tests, which help determine disease stage, verify infection, and track patient response to treatment. This testing is vital for reducing disease spread, protecting maternal and infant health, and managing complications. It is particularly significant for individuals at higher risk or with possible exposure to sexually transmitted infections.
Market Dynamics:
Driver:
Increased routine screening programs
The rising implementation of routine syphilis screening initiatives is significantly boosting market demand. Public health agencies are intensifying efforts to detect infections early, especially among high-risk populations such as pregnant women and individuals with HIV. Technological advancements in rapid point-of-care tests are enabling broader deployment across clinics and outreach settings. Integration with digital health platforms is streamlining patient tracking and follow-up diagnostics. Emerging trends include AI-assisted screening algorithms and mobile-based testing kits that improve accessibility. As governments expand STI surveillance programs, syphilis testing is becoming a core component of preventive healthcare strategies.
Restraint:
Inadequate healthcare infrastructure and access
Many low-income countries face shortages in trained personnel, laboratory capacity, and essential testing supplies. Infrastructure gaps are especially pronounced in antenatal care settings, where early detection of congenital syphilis is critical. The lack of digital connectivity further restricts integration with centralized health systems. While mobile clinics and telemedicine offer partial solutions, scalability remains a challenge. Without sustained investment in healthcare infrastructure, syphilis testing coverage will remain uneven across geographies.
Opportunity:
Integration of multiplex and dual-purpose tests
Dual-purpose assays that detect multiple STIs simultaneously are gaining traction in both clinical and public health settings. These platforms reduce turnaround time, improve cost-efficiency, and enhance patient compliance. Advances in microfluidics and biosensor technologies are enabling compact, multi-analyte devices suitable for decentralized use. Regulatory bodies are increasingly supporting bundled testing protocols to streamline care delivery. As personalized medicine evolves, multiplex syphilis tests are expected to play a pivotal role in integrated sexual health diagnostics.
Threat:
Competition from other STI diagnostics
Tests for HIV, chlamydia, and gonorrhea often dominate procurement budgets and public health priorities. Multi-pathogen panels may dilute focus on syphilis-specific innovations unless bundled strategically. Rapid developments in molecular diagnostics and CRISPR-based detection are shifting attention toward newer technologies. Market fragmentation is also driven by regional preferences for certain test formats or brands.
Covid-19 Impact
The pandemic disrupted routine STI screening programs, leading to delayed diagnoses and reduced testing volumes. Lockdowns and resource reallocation toward Covid-19 diagnostics strained laboratory capacity and supply chains. However, the crisis accelerated adoption of remote testing kits and digital reporting platforms for STIs. Emergency regulatory pathways enabled faster approval of novel syphilis assays, including self-testing formats. Post-pandemic strategies now emphasize resilience, decentralized diagnostics, and integration with pandemic preparedness frameworks.
The congenital syphilis segment is expected to be the largest during the forecast period
The congenital syphilis segment is expected to account for the largest market share during the forecast period, due to its critical public health implications. Rising maternal screening mandates and improved prenatal care protocols are driving demand for early detection tools. Technological advances in rapid treponemal tests are enabling timely intervention during pregnancy. Governments are prioritizing congenital syphilis elimination through targeted funding and surveillance programs. Integration with electronic health records is improving case tracking and follow-up treatment. As awareness grows, congenital syphilis testing is becoming a cornerstone of maternal and neonatal health strategies.
The public health programs segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the public health programs segment is predicted to witness the highest growth rate, driven by expanding STI control initiatives worldwide. National and regional campaigns are scaling up syphilis screening through mobile units, community outreach, and school-based interventions. Adoption of cloud-based data systems is enhancing program monitoring and epidemiological insights. Innovations in low-cost, high-throughput testing platforms are making mass screening more feasible. Partnerships between NGOs, governments, and diagnostic firms are accelerating deployment in high-burden areas. As global health priorities shift toward STI elimination, public health programs will be central to market expansion.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising healthcare investments and population-wide screening efforts. Countries like China, India, and Indonesia are scaling up STI diagnostics through national health missions and digital health rollouts. Local manufacturing of test kits is improving affordability and supply chain resilience. Emerging trends include AI-powered diagnostic platforms and mobile testing labs tailored for remote regions. Strategic collaborations between global and regional players are enhancing technology transfer and market penetration.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by technological leadership and robust public health infrastructure. The U.S. and Canada are investing heavily in next-gen STI diagnostics, including molecular and AI-enhanced platforms. Regulatory agencies are streamlining approvals for innovative syphilis tests, including home-based and telehealth-compatible formats. Integration with electronic medical records and predictive analytics is improving case management and outbreak response. Reimbursement frameworks are increasingly supportive of routine STI screening, especially in underserved communities.
Key players in the market
Some of the key players profiled in the Syphilis Testing Market include Abbott Laboratories, SD Biosensor, Roche Diagnostics, Trinity Biotech, Siemens Healthineers, MedMira Inc., Thermo Fisher Scientific, Fujirebio, Bio-Rad Laboratories, QuidelOrtho Corporation, Danaher Corporation, bioMérieux, Becton, Dickinson and Company (BD), OraSure Technologies, and Hologic Inc.
Key Developments:
In September 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc. a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio’s pegozafermin is a FGF21 analog currently in late-stage development for MASH.
In February 2025, Abbott and Shedd Aquarium are announcing one of Shedd’s largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.
Types Covered:
• Primary Syphilis
• Secondary Syphilis
• Congenital Syphilis
• Latent Syphilis
• Other Types
Location of Testings Covered:
• Laboratory-Based Testing
• Home-Based Testing
• Point-of-Care Testing
Technologies Covered:
• Immunoassay
• Molecular Diagnostics
• Multiplex Platforms
• Other Technologies
Distribution Channels Covered:
• Direct Sales
• Online Pharmacies
• Retail Pharmacies
Applications Covered:
• Hospitals
• Clinics
• Public Health Programs
• Diagnostic Laboratories
• Other Applications
End Users Covered:
• Public Healthcare Facilities
• Private Healthcare Providers
• NGOs and Community Health Centers
• Other End Users
Regions Covered:
• North America US Canada Mexico
• Europe Germany UK Italy France Spain Rest of Europe
• Asia Pacific Japan China India Australia New Zealand South Korea Rest of Asia Pacific
• South America Argentina Brazil Chile Rest of South America
• Middle East & Africa Saudi Arabia UAE Qatar South Africa Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Market Dynamics:
Driver:
Increased routine screening programs
The rising implementation of routine syphilis screening initiatives is significantly boosting market demand. Public health agencies are intensifying efforts to detect infections early, especially among high-risk populations such as pregnant women and individuals with HIV. Technological advancements in rapid point-of-care tests are enabling broader deployment across clinics and outreach settings. Integration with digital health platforms is streamlining patient tracking and follow-up diagnostics. Emerging trends include AI-assisted screening algorithms and mobile-based testing kits that improve accessibility. As governments expand STI surveillance programs, syphilis testing is becoming a core component of preventive healthcare strategies.
Restraint:
Inadequate healthcare infrastructure and access
Many low-income countries face shortages in trained personnel, laboratory capacity, and essential testing supplies. Infrastructure gaps are especially pronounced in antenatal care settings, where early detection of congenital syphilis is critical. The lack of digital connectivity further restricts integration with centralized health systems. While mobile clinics and telemedicine offer partial solutions, scalability remains a challenge. Without sustained investment in healthcare infrastructure, syphilis testing coverage will remain uneven across geographies.
Opportunity:
Integration of multiplex and dual-purpose tests
Dual-purpose assays that detect multiple STIs simultaneously are gaining traction in both clinical and public health settings. These platforms reduce turnaround time, improve cost-efficiency, and enhance patient compliance. Advances in microfluidics and biosensor technologies are enabling compact, multi-analyte devices suitable for decentralized use. Regulatory bodies are increasingly supporting bundled testing protocols to streamline care delivery. As personalized medicine evolves, multiplex syphilis tests are expected to play a pivotal role in integrated sexual health diagnostics.
Threat:
Competition from other STI diagnostics
Tests for HIV, chlamydia, and gonorrhea often dominate procurement budgets and public health priorities. Multi-pathogen panels may dilute focus on syphilis-specific innovations unless bundled strategically. Rapid developments in molecular diagnostics and CRISPR-based detection are shifting attention toward newer technologies. Market fragmentation is also driven by regional preferences for certain test formats or brands.
Covid-19 Impact
The pandemic disrupted routine STI screening programs, leading to delayed diagnoses and reduced testing volumes. Lockdowns and resource reallocation toward Covid-19 diagnostics strained laboratory capacity and supply chains. However, the crisis accelerated adoption of remote testing kits and digital reporting platforms for STIs. Emergency regulatory pathways enabled faster approval of novel syphilis assays, including self-testing formats. Post-pandemic strategies now emphasize resilience, decentralized diagnostics, and integration with pandemic preparedness frameworks.
The congenital syphilis segment is expected to be the largest during the forecast period
The congenital syphilis segment is expected to account for the largest market share during the forecast period, due to its critical public health implications. Rising maternal screening mandates and improved prenatal care protocols are driving demand for early detection tools. Technological advances in rapid treponemal tests are enabling timely intervention during pregnancy. Governments are prioritizing congenital syphilis elimination through targeted funding and surveillance programs. Integration with electronic health records is improving case tracking and follow-up treatment. As awareness grows, congenital syphilis testing is becoming a cornerstone of maternal and neonatal health strategies.
The public health programs segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the public health programs segment is predicted to witness the highest growth rate, driven by expanding STI control initiatives worldwide. National and regional campaigns are scaling up syphilis screening through mobile units, community outreach, and school-based interventions. Adoption of cloud-based data systems is enhancing program monitoring and epidemiological insights. Innovations in low-cost, high-throughput testing platforms are making mass screening more feasible. Partnerships between NGOs, governments, and diagnostic firms are accelerating deployment in high-burden areas. As global health priorities shift toward STI elimination, public health programs will be central to market expansion.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising healthcare investments and population-wide screening efforts. Countries like China, India, and Indonesia are scaling up STI diagnostics through national health missions and digital health rollouts. Local manufacturing of test kits is improving affordability and supply chain resilience. Emerging trends include AI-powered diagnostic platforms and mobile testing labs tailored for remote regions. Strategic collaborations between global and regional players are enhancing technology transfer and market penetration.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by technological leadership and robust public health infrastructure. The U.S. and Canada are investing heavily in next-gen STI diagnostics, including molecular and AI-enhanced platforms. Regulatory agencies are streamlining approvals for innovative syphilis tests, including home-based and telehealth-compatible formats. Integration with electronic medical records and predictive analytics is improving case management and outbreak response. Reimbursement frameworks are increasingly supportive of routine STI screening, especially in underserved communities.
Key players in the market
Some of the key players profiled in the Syphilis Testing Market include Abbott Laboratories, SD Biosensor, Roche Diagnostics, Trinity Biotech, Siemens Healthineers, MedMira Inc., Thermo Fisher Scientific, Fujirebio, Bio-Rad Laboratories, QuidelOrtho Corporation, Danaher Corporation, bioMérieux, Becton, Dickinson and Company (BD), OraSure Technologies, and Hologic Inc.
Key Developments:
In September 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc. a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio’s pegozafermin is a FGF21 analog currently in late-stage development for MASH.
In February 2025, Abbott and Shedd Aquarium are announcing one of Shedd’s largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.
Types Covered:
• Primary Syphilis
• Secondary Syphilis
• Congenital Syphilis
• Latent Syphilis
• Other Types
Location of Testings Covered:
• Laboratory-Based Testing
• Home-Based Testing
• Point-of-Care Testing
Technologies Covered:
• Immunoassay
• Molecular Diagnostics
• Multiplex Platforms
• Other Technologies
Distribution Channels Covered:
• Direct Sales
• Online Pharmacies
• Retail Pharmacies
Applications Covered:
• Hospitals
• Clinics
• Public Health Programs
• Diagnostic Laboratories
• Other Applications
End Users Covered:
• Public Healthcare Facilities
• Private Healthcare Providers
• NGOs and Community Health Centers
• Other End Users
Regions Covered:
• North America US Canada Mexico
• Europe Germany UK Italy France Spain Rest of Europe
• Asia Pacific Japan China India Australia New Zealand South Korea Rest of Asia Pacific
• South America Argentina Brazil Chile Rest of South America
• Middle East & Africa Saudi Arabia UAE Qatar South Africa Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Table of Contents
200 Pages
- 1 Executive Summary
- 2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
- 3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 Application Analysis
- 3.8 End User Analysis
- 3.9 Emerging Markets
- 3.10 Impact of Covid-19
- 4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
- 5 Global Syphilis Testing Market, By Type
- 5.1 Introduction
- 5.2 Primary Syphilis
- 5.3 Secondary Syphilis
- 5.4 Congenital Syphilis
- 5.5 Latent Syphilis
- 5.6 Other Types
- 6 Global Syphilis Testing Market, By Location of Testing
- 6.1 Introduction
- 6.2 Laboratory-Based Testing
- 6.3 Home-Based Testing
- 6.4 Point-of-Care Testing
- 7 Global Syphilis Testing Market, By Technology
- 7.1 Introduction
- 7.2 Immunoassay
- 7.3 Molecular Diagnostics
- 7.4 Multiplex Platforms
- 7.5 Other Technologies
- 8 Global Syphilis Testing Market, By Distribution Channel
- 8.1 Introduction
- 8.2 Direct Sales
- 8.3 Online Pharmacies
- 8.4 Retail Pharmacies
- 9 Global Syphilis Testing Market, By Application
- 9.1 Introduction
- 9.2 Hospitals
- 9.3 Clinics
- 9.4 Public Health Programs
- 9.5 Diagnostic Laboratories
- 9.6 Other Applications
- 10 Global Syphilis Testing Market, By End User
- 10.1 Introduction
- 10.2 Public Healthcare Facilities
- 10.3 Private Healthcare Providers
- 10.4 NGOs and Community Health Centers
- 10.5 Other End Users
- 11 Global Syphilis Testing Market, By Geography
- 11.1 Introduction
- 11.2 North America
- 11.2.1 US
- 11.2.2 Canada
- 11.2.3 Mexico
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 Italy
- 11.3.4 France
- 11.3.5 Spain
- 11.3.6 Rest of Europe
- 11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 New Zealand
- 11.4.6 South Korea
- 11.4.7 Rest of Asia Pacific
- 11.5 South America
- 11.5.1 Argentina
- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
- 11.6 Middle East & Africa
- 11.6.1 Saudi Arabia
- 11.6.2 UAE
- 11.6.3 Qatar
- 11.6.4 South Africa
- 11.6.5 Rest of Middle East & Africa
- 12 Key Developments
- 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 12.2 Acquisitions & Mergers
- 12.3 New Product Launch
- 12.4 Expansions
- 12.5 Other Key Strategies
- 13 Company Profiling
- 13.1 Abbott Laboratories
- 13.2 SD Biosensor
- 13.3 Roche Diagnostics
- 13.4 Trinity Biotech
- 13.5 Siemens Healthineers
- 13.6 MedMira Inc.
- 13.7 Thermo Fisher Scientific
- 13.8 Fujirebio
- 13.9 Bio-Rad Laboratories
- 13.10 QuidelOrtho Corporation
- 13.11 Danaher Corporation
- 13.12 bioMérieux
- 13.13 Becton, Dickinson and Company (BD)
- 13.14 OraSure Technologies
- 13.15 Hologic Inc.
- List of Tables
- Table 1 Global Syphilis Testing Market Outlook, By Region (2024-2032) ($MN)
- Table 2 Global Syphilis Testing Market Outlook, By Type (2024-2032) ($MN)
- Table 3 Global Syphilis Testing Market Outlook, By Primary Syphilis (2024-2032) ($MN)
- Table 4 Global Syphilis Testing Market Outlook, By Secondary Syphilis (2024-2032) ($MN)
- Table 5 Global Syphilis Testing Market Outlook, By Congenital Syphilis (2024-2032) ($MN)
- Table 6 Global Syphilis Testing Market Outlook, By Latent Syphilis (2024-2032) ($MN)
- Table 7 Global Syphilis Testing Market Outlook, By Other Types (2024-2032) ($MN)
- Table 8 Global Syphilis Testing Market Outlook, By Location of Testing (2024-2032) ($MN)
- Table 9 Global Syphilis Testing Market Outlook, By Laboratory-Based Testing (2024-2032) ($MN)
- Table 10 Global Syphilis Testing Market Outlook, By Home-Based Testing (2024-2032) ($MN)
- Table 11 Global Syphilis Testing Market Outlook, By Point-of-Care Testing (2024-2032) ($MN)
- Table 12 Global Syphilis Testing Market Outlook, By Technology (2024-2032) ($MN)
- Table 13 Global Syphilis Testing Market Outlook, By Immunoassay (2024-2032) ($MN)
- Table 14 Global Syphilis Testing Market Outlook, By Molecular Diagnostics (2024-2032) ($MN)
- Table 15 Global Syphilis Testing Market Outlook, By Multiplex Platforms (2024-2032) ($MN)
- Table 16 Global Syphilis Testing Market Outlook, By Other Technologies (2024-2032) ($MN)
- Table 17 Global Syphilis Testing Market Outlook, By Distribution Channel (2024-2032) ($MN)
- Table 18 Global Syphilis Testing Market Outlook, By Direct Sales (2024-2032) ($MN)
- Table 19 Global Syphilis Testing Market Outlook, By Online Pharmacies (2024-2032) ($MN)
- Table 20 Global Syphilis Testing Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
- Table 21 Global Syphilis Testing Market Outlook, By Application (2024-2032) ($MN)
- Table 22 Global Syphilis Testing Market Outlook, By Hospitals (2024-2032) ($MN)
- Table 23 Global Syphilis Testing Market Outlook, By Clinics (2024-2032) ($MN)
- Table 24 Global Syphilis Testing Market Outlook, By Public Health Programs (2024-2032) ($MN)
- Table 25 Global Syphilis Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
- Table 26 Global Syphilis Testing Market Outlook, By Other Applications (2024-2032) ($MN)
- Table 27 Global Syphilis Testing Market Outlook, By End User (2024-2032) ($MN)
- Table 28 Global Syphilis Testing Market Outlook, By Public Healthcare Facilities (2024-2032) ($MN)
- Table 29 Global Syphilis Testing Market Outlook, By Private Healthcare Providers (2024-2032) ($MN)
- Table 30 Global Syphilis Testing Market Outlook, By NGOs and Community Health Centers (2024-2032) ($MN)
- Table 31 Global Syphilis Testing Market Outlook, By Other End Users (2024-2032) ($MN)
- Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
